|
1
|
Gill JS: Cardiovascular disease in
transplant recipients: current and future treatment strategies.
Clin J Am Soc Nephrol. 3(Suppl 2): S29–S37. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bruschi G, Colombo T, Oliva F, et al:
Heart transplantation: 25 years’ single-centre experience. J
Cardiovasc Med (Hagerstown). 14:637–647. 2013.
|
|
3
|
Fiorelli AI, Branco JN, Dinkhuysen JJ, et
al: Risk factor analysis of late survival after heart
transplantation according to donor profile: a multi-institutional
retrospective study of 512 transplants. Transplant Proc.
44:2469–2472. 2012. View Article : Google Scholar
|
|
4
|
Suzuki J, Ogawa M, Hirata Y, Nagai R and
Isobe M: Effects of immunoglobulin to prevent coronary allograft
vasculopathy in heart transplantation. Expert Opin Ther Targets.
16:783–789. 2012. View Article : Google Scholar
|
|
5
|
Tedoriya T, MacDonald PS, Keogh AM, Wilson
M and Spratt PM: Reversal of chronic cyclosporin nephrotoxicity
after heart transplantation. J Heart Lung Transplant. 20:247–248.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Aumente MD, Arizón JM, Segura J, et al:
Relationship between pharmacokinetic parameters of cyclosporin and
the incidence of acute rejection after heart transplantation.
Transplant Proc. 37:4014–4017. 2005. View Article : Google Scholar
|
|
7
|
Baan CC, Vaessen LM, Balk AH, et al:
Cyclosporin A sensitivity of allo-specific precursor and committed
cytotoxic T lymphocytes after clinical heart transplantation.
Transplant Proc. 26:2849–2851. 1994.PubMed/NCBI
|
|
8
|
Werkö L: Cyclosporin as a cause of
hypertension in patients with heart transplantation.
Lakartidningen. 88:5031991.(In Swedish).
|
|
9
|
Huang XP, Sun Z, Miyagi Y, et al:
Differentiation of allogeneic mesenchymal stem cells induces
immunogenicity and limits their long-term benefits for myocardial
repair. Circulation. 122:2419–2429. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Espino J, Pariente JA and Rodríguez AB:
Oxidative stress and immunosenescence: therapeutic effects of
melatonin. Oxid Med Cell Longev. 2012:6702942012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fildes JE, Yonan N and Keevil BG:
Melatonin - a pleiotropic molecule involved in pathophysiological
processes following organ transplantation. Immunology. 127:443–449.
2009. View Article : Google Scholar
|
|
12
|
Gilad E, Wong HR, Zingarelli B, et al:
Melatonin inhibits expression of the inducible isoform of nitric
oxide synthase in murine macrophages: role of inhibition of
NFkappaB activation. Faseb J. 12:685–693. 1998.PubMed/NCBI
|
|
13
|
Jung FJ, Yang L, Härter L, et al:
Melatonin in vivo prolongs cardiac allograft survival in rats. J
Pineal Res. 37:36–41. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cardell M, Jung FJ, Zhai W, et al: Acute
allograft rejection and immunosuppression: influence on endogenous
melatonin secretion. J Pineal Res. 44:261–266. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eşrefoğlu M1, Kuruş M and Sahna E: The
beneficial effect of melatonin on chronic cyclosporin A
nephrotoxicity in rats. J Int Med Res. 31:42–44. 2003.PubMed/NCBI
|
|
16
|
Rezzani R, Buffoli B, Rodella L,
Stacchiotti A and Bianchi R: Protective role of melatonin in
cyclosporine A-induced oxidative stress in rat liver. Int
Immunopharmacol. 5:1397–1405. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yoo YM and Jeung EB: Melatonin suppresses
cyclosporine A-induced autophagy in rat pituitary GH3 cells. J
Pineal Res. 48:204–211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jessup M, Banner N, Brozena S, et al:
Optimal pharmacologic and non-pharmacologic management of cardiac
transplant candidates: approaches to be considered prior to
transplant evaluation: International Society for Heart and Lung
Transplantation guidelines for the care of cardiac transplant
candidates - 2006. J Heart Lung Transplant. 25:1003–1023. 2006.
|
|
19
|
Carrillo-Vico A, Lardone PJ, Naji L, et
al: Beneficial pleiotropic actions of melatonin in an experimental
model of septic shock in mice: regulation of pro-/anti-inflammatory
cytokine network, protection against oxidative damage and
anti-apoptotic effects. J Pineal Res. 39:400–408. 2005. View Article : Google Scholar
|
|
20
|
Santello FH, Frare EO, Caetano LC,
AlonsoToldo MP and do Prado JC Jr: Melatonin enhances
pro-inflammatory cytokine levels and protects against Chagas
disease. J Pineal Res. 45:79–85. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tang EH, Libby P, Vanhoutte PM and Xu A:
Anti-inflammation therapy by activation of prostaglandin EP4
receptor in cardiovascular and other inflammatory diseases. J
Cardiovasc Pharmacol. 59:116–123. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wolters SL, Corsten MF, Reutelingsperger
CP, Narula J and Hofstra L: Cardiovascular molecular imaging of
apoptosis. Eur J Nucl Med Mol Imaging. 34(Suppl 1): S86–S98. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Szabolcs M, Michler RE, Yang X, et al:
Apoptosis of cardiac myocytes during cardiac allograft rejection.
Relation to induction of nitric oxide synthase. Circulation.
94:1665–1673. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gedik HS, Korkmaz K, Erdem H, Karakilic E,
Lafci G and Ankarali H: Protective effect of heparin in the end
organ ischemia/reperfusion injury of the lungs and heart. J
Cardiothorac Surg. 7:1232012. View Article : Google Scholar : PubMed/NCBI
|
